RagweedMATAMPL

BIOLOGICAL2 trials

Sponsors

Allergy Therapeutics

Conditions

Type I Hypersensitivity

Phase 1

Evaluation of Safety and Tolerability of Tyrosine Adsorbed Ragweed Pollen Allergoid With MPL (Monophosphoryl Lipid A)

WithdrawnNCT00109759

Allergy TherapeuticsType I Hypersensitivity

Start: 2005-05-31End: 2005-06-30Updated: 2021-08-12

Phase 2

Investigation of Safety+Efficacy of Different Doses of RagweedMATAMPL;Assessment of Residual Allergenicity Using Skin Prick Test

CompletedNCT00258635

Allergy TherapeuticsType I Hypersensitivity

Start: 2005-11-30End: 2006-08-07Updated: 2021-06-11